Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-03-12

Clinical Trial Update: Pazopanib in Second-line Therapy in Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial update evaluating pazopanib as second-line therapy for metastatic renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Votrient (Pazopanib)

Snippet

Sponsor: Associació per a la Recerca Oncologica, Spain | Conditions: Metastatic Renal Cell Carcinoma | Phase 2 | Status: UNKNOWN